IDT Stock Overview
IDT Australia Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (APIs) and finished dose form products in Australia and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
IDT Australia Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.095 |
| 52 Week High | AU$0.13 |
| 52 Week Low | AU$0.05 |
| Beta | 1.21 |
| 1 Month Change | 18.75% |
| 3 Month Change | -9.52% |
| 1 Year Change | 25.00% |
| 3 Year Change | -76.83% |
| 5 Year Change | -40.63% |
| Change since IPO | -39.19% |
Recent News & Updates
Recent updates
IDT Australia (ASX:IDT) Is Using Debt Safely
Apr 08
IDT Australia Limited's (ASX:IDT) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/E Ratio
Mar 04Here's Why Shareholders Will Not Be Complaining About IDT Australia Limited's (ASX:IDT) CEO Pay Packet
Nov 09IDT Australia's (ASX:IDT) Promising Earnings May Rest On Soft Foundations
Aug 31Is IDT Australia's (ASX:IDT) 280% Share Price Increase Well Justified?
Mar 20IDT Australia (ASX:IDT) Is In A Good Position To Deliver On Growth Plans
Jan 13Does IDT Australia's (ASX:IDT) CEO Salary Compare Well With The Performance Of The Company?
Dec 09
Shareholder Returns
| IDT | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 8.0% | -3.0% | -2.2% |
| 1Y | 25.0% | 37.1% | 4.5% |
Return vs Industry: IDT underperformed the Australian Pharmaceuticals industry which returned 32.4% over the past year.
Return vs Market: IDT exceeded the Australian Market which returned 4% over the past year.
Price Volatility
| IDT volatility | |
|---|---|
| IDT Average Weekly Movement | 9.7% |
| Pharmaceuticals Industry Average Movement | 11.1% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: IDT has not had significant price volatility in the past 3 months.
Volatility Over Time: IDT's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1975 | n/a | Paul McDonald | en.idtaus.com.au |
IDT Australia Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (APIs) and finished dose form products in Australia and internationally. It offers analytical method development, stability chambers, chemistry and microbiology quality control laboratory, and quality assurance services. The company also provides project management, chemical, analytical chemistry, pharmacy, clinical packaging, and regulatory affairs, as well as pharmaceutical development services in various dosage forms.
IDT Australia Limited Fundamentals Summary
| IDT fundamental statistics | |
|---|---|
| Market cap | AU$33.39m |
| Earnings (TTM) | -AU$6.54m |
| Revenue (TTM) | AU$10.33m |
3.2x
P/S Ratio-5.1x
P/E RatioIs IDT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IDT income statement (TTM) | |
|---|---|
| Revenue | AU$10.33m |
| Cost of Revenue | AU$5.99m |
| Gross Profit | AU$4.34m |
| Other Expenses | AU$10.88m |
| Earnings | -AU$6.54m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.019 |
| Gross Margin | 42.00% |
| Net Profit Margin | -63.35% |
| Debt/Equity Ratio | 10.0% |
How did IDT perform over the long term?
See historical performance and comparison